RxDoctor Payments Data

Jenny Nguyen

Nurse Practitioner · Las Vegas, NVNPI 1629583638

Payments from drug & device makers

$4,596in general payments, 2019–2025

Across 60 payments — averaging $76.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$1K
  • MDD US Operations, LLC$1K
  • AbbVie$970
  • Acadia Pharmaceuticals Inc$702
  • Abbott$332
  • Biogen$92
  • plus $153 from 4 others

What the payments were for

  • Consulting fees$79417%
  • Speaking & faculty fees$2,10246%
  • Food & beverage$1,69937%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,596 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$142,964
Medicare patients
243
Services billed
9,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate86$443,382
RytaryCarbidopa/Levodopa237$395,896
GocovriAmantadine Hcl61$226,629
IngrezzaValbenazine Tosylate12$100,127
XadagoSafinamide Mesylate28$64,998
Tetrabenazine12$28,982
NeuproRotigotine14$23,105
Carbidopa-LevodopaCarbidopa/Levodopa443$13,624
OngentysOpicapone12$11,446
AmantadineAmantadine Hcl149$10,894
Rasagiline Mesylate46$7,566
Carbidopa-Levodopa ErCarbidopa/Levodopa171$6,219
Rivastigmine21$2,806
Primidone47$2,029
Ropinirole ErRopinirole Hcl17$1,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$702$443,38286 claims
Amneal Pharmaceuticals LLCRytary$1,266$395,896237 claims
MDD US Operations, LLCGocovri$1,080$226,62961 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$37$111,57324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →